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ABSTRACT
OBJECTIVE: To estimate hospitalization rates for pneumococcal disease based 
on the Brazilian Hospital Information System (SIH).
METHODS: Descriptive study based on the Hospital Information System 
of Brazilian National Health System data from January 2004 to December 
2006: number of hospitalizations and deaths for pneumococcal meningitis, 
pneumococcal sepsis, pneumococcal pneumonia and Streptococcus 
pneumoniae as the cause of diseases reported in Brazil. Data from the 2003 
Brazilian National Household Survey were used to estimate events in the 
private sector. Pneumococcal meningitis cases and deaths reported to the 
Notifi able Diseases Information System during the study period were also 
analyzed.
RESULTS: Pneumococcal disease accounted for 34,217 hospitalizations in 
the Brazilian National Health System (0.1% of all hospitalizations in the 
public sector). Pneumococcal pneumonia accounted for 64.8% of these 
hospitalizations. The age distribution of the estimated hospitalization rates 
for pneumococcal disease showed a “U”-shape curve with the highest rates 
seen in children under one (110 to 136.9 per 100,000 children annually). The 
highest hospital case-fatality rates were seen among the elderly, and for sepsis 
and meningitis.
CONCLUSIONS: PD is a major public health problem in Brazil. The analysis 
based on the SIH can provide an important input to pneumococcal disease 
surveillance and the impact assessment of immunization programs.
DESCRIPTORS: Pneumococcal Infections, epidemiology. Pneumonia, 
Pneumococcal. Meningitis, Pneumococcal. Sepsis. Hospitalization. 
Epidemiologic Surveillance.
Artigos Originais
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Streptococcus pneumoniae is a major cause of illness 
and death worldwide. Clinical manifestations of pneu-
mococcal infection include serious life-threatening 
invasive disease – meningitis, sepsis, pneumonia 
with bacteremia, and other conditions such as bone 
and joint infection and peritonitis. Pneumococcus 
also causes non-invasive diseases such as pneumonia 
without bacteremia, bronchitis, sinusitis, and otitis 
media, which accounts for most pneumococcal-related 
disease. S. pneumonia is the most common cause of 
invasive bacterial disease in children in countries with 
universal childhood immunization programs against 
Haemophilus infl uenza type b.1
There are available safe and effective vaccines to 
prevent pneumococcal disease (PD) in children under 
two. The heptavalent pneumococcal conjugate vaccine 
(PCV7) has shown signifi cant impact in reducing PD 
rates in countries where universal childhood immuni-
zation programs have been implemented.8,21 Both the 
10-valent (PCV10) and the 13-valent conjugate pneumo-
coccal vaccines have recently been made available.5,26
In Brazil, the PCV7 has been available in the Brazilian 
National Health System (Sistema Único de Saúde, SUS) 
RESUMO
OBJETIVO: Estimar as hospitalizações por doença pneumocócica com base 
em dados do Sistema de Informações Hospitalares (SIH).
MÉTODOS: Estudo descritivo com base em dados do SIH de janeiro 
de 2004 a dezembro de 2006: números de hospitalizações e mortes por 
meningite pneumocócica, sepse pneumocócica, pneumonia pneumocócicca e 
Streptococcus pneumoniae como causa de doenças ocorridas no Brasil. Dados 
da Pesquisa Nacional por Amostras de Domicílios 2003 foram utilizados para 
o setor privado. Casos e mortes por meningite pneumocócica notifi cados no 
Sistema Nacional de Agravos de Notifi cação no mesmo período também 
foram analisados.
RESULTADOS: A doença pneumocócica foi responsável por 34.217 
hospitalizações no Sistema Único de Saúde (0,1% de todas as hospitalizações). 
Pneumonia pneumocócica foi responsável por 64,8% dessas hospitalizações. 
A distribuição das estimativas de hospitalizações segundo faixa etária mostrou 
curva em “U”, com maior freqüência entre crianças < 1 ano (110-136,9/100.000 
crianças/ano). A letalidade hospitalar foi mais alta entre idosos, e entre casos 
de meningite e sepse. 
CONCLUSÕES: Doença pneumocócica é importante problema de saúde 
pública no Brasil. Análise baseada no SIH pode contribuir para a vigilância 
epidemiológica da doença pneumocócica e para a avaliação do impacto do 
programa de vacinação.
DESCRITORES: Infecções Pneumocócicas, epidemiologia. Pneumonia 
Pneumocócica. Meningite Pneumocócica. Sepse. Hospitalização. 
Vigilância Epidemiológica.
INTRODUCTION
since 2002, but only for children under fi ve with high 
risk of PD. This strategy has resulted in low vaccine 
coverage as we estimated based on administrative 
data that less than 5% of children under 12 months 
were vaccinated in 2009. The 23-valent pneumococcal 
polysaccharide vaccine is also available for the elderly 
(≥ 60 years), and adults and children two years of age 
and older with chronic conditions. In March 2010, the 
PCV10 was introduced for routine immunization of 
infants (four doses at two, four, six and 12 months of 
age) with catch-up vaccination for children under two 
in the fi rst year of the program. Effective surveillance 
of PD is essential to monitor this program’s impact.
Pneumococcal surveillance systems focusing on 
invasive pneumococcal disease (IPD) are very hetero-
geneous and have different notifi cation rules, case defi -
nitions, case reporting coverage, data collection, health 
information system utilization, quantity and quality of 
laboratories so data comparability is a problem.18
A laboratory-based surveillance system of IPD has 
been active in Brazil since 1993 (Network Surveillance 
System for the Bacterial Agents Responsible for 
Pneumonia and Meningitis, Sistema Regional de 
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Vacinas – SIREVA II). This network provides data on 
pneumococcus serotype distribution and antimicrobial 
resistance but with limited population coverage. The 
linking of laboratory data with epidemiological and 
clinical information needs to be strengthened.3
The use of data based on clinical diagnosis, hospital 
admissions and outpatient consultations in pneumo-
coccal burden of disease studies and surveillance 
systems has been limited as recent reviews of vaccine 
impact studies in the US and Europe have shown.8,21 
The clinical diagnosis has high sensitivity but low 
specifi city for PD, and laboratory-based systems have 
been prioritized, particularly for IPD. Hospital admis-
sions and consultations have more often been used to 
estimate pneumococcal pneumonia and otitis due to 
the limited contribution of diagnostic laboratory tests 
in these conditions.
A population-based time series analysis based on 
hospital admissions data have shown that this is a 
feasible, valid and useful approach for measuring 
the impact of pneumococcal conjugate immunization 
programs, especially when there are good quality 
national hospital databases with clear inclusion criteria 
and appropriate methodological strategies. Studies in 
England and Wales, US and Australia have shown 
similar tendencies for PD decline and seasonal varia-
tion when comparing active surveillance and hospital 
information data.8,15,19
The Brazilian National Health System provides a free-
access, good quality national hospital database (Sistema 
de Informações Hospitalares – SIH) and estimates of 
hospitalization and case-fatality rates for PD in Brazil 
may effectively and effi ciently contribute to the asses-
sment of the potential impact of an universal childhood 
pneumococcal immunization program.13
The present study aimed to estimate hospitalization 
rates for PD in Brazil based on SIH-SUS data.
METHODS
A descriptive study based on SIH-SUS data was 
conducted. Data on hospital admissions, which 
occurred from January 1st, 2004 to December 31st, 2006, 
due to the clinical syndromes of interest – pneumo-
coccal meningitis, pneumococcal sepsis, pneumococcal 
pneumonia and S. pneumoniae as the cause of diseases – 
as the main diagnosis were obtained from the SIH-SUS. 
This database has information on individual cases of 
illness with data on patient demographic characteristics, 
length of hospital stay, diagnoses at discharge, disease 
outcome, and hospital reimbursement rates.
Since the SIH-SUS covers only the public sector, 
estimates of hospitalizations in the private sector were 
calculated to obtain national population estimates. Data 
from the 2003 Brazilian National Household Survey 
showed 72.9% of all clinical hospitalizations were in 
the SUS and were used to estimate hospitalization rates 
in the private sector.4
Meningitis is a mandatory notifi able disease in Brazil, 
and data from the Notifi able Diseases Database (Sistema 
de Informação de Agravos de Notifi cação  – SINAN) for 
the same period were also analyzed. SINAN database 
includes aggregate data on population frequency of 
notifi able diseases and their outcomes according to age 
group, clinical syndromes and etiological agents, and 
good quality information on meningitis.13
Annual age-specifi c hospitalization rates for PD were 
calculated using the total number of hospitalizations 
for each clinical syndrome based on SIH-SUS data and 
population estimates in Brazil for each year studied 
obtained from the Instituto Brasileiro de Geografi a 
e Estatística (Brazilian Institute of Geography and 
Statistics).
For population estimates of annual age-specifi c hospita-
lization rates for PD, in addition to estimating the rates 
in the private sector, we also included the estimated 
number of cases of pneumococcal meningitis reported 
under the diagnosis “unspecifi ed bacterial meningitis”.
Case-fatality was defined as in-hospital death. 
Age-specifi c case-fatality rates (CFR) were estimated 
based on the number of deaths/confi rmed cases for 
each clinical syndrome registered in the SIH-SUS and 
SINAN.
A search was performed using the International 
Classifi cation of Diseases – 10th Revision (ICD-10) 
codes: A40.3 – pneumococcal sepsis; G00.1 – pneu-
mococcal meningitis; J13 – pneumococcal pneumonia; 
and B95.3 – S. pneumoniae as the cause of diseases. 
The numbers of hospitalizations for related syndromes 
(meningococcal meningitis – A39.0, Haemophilus 
meningitis – G00.0, meningitis due to other bacteria 
– G00.2, G00.3 and G00.8, unspecified bacterial 
meningitis – G40.3, unspecifi ed sepsis – A41.9, all 
causes sepsis – A40-A41, and all causes pneumonia – 
J12-J18) were also obtained to assess the relationship 
of pneumococcal hospitalizations with these clinical 
syndromes. SIH data were retrieved from CDs provided 
by DATASUS (SIH data for 2004 and 2005 were 
recorded on 20 December 2007; data for 2006 were 
recorded on 28 November 2008). SINAN was accessed 
online on February 2009.
RESULTS
In the three-year study period there were 34,217 hospi-
talizations for PD in the SIH-SUS database, accounting 
for 0.1% of all hospitalizations (34,260,055) in the 
public sector in Brazil. Of these, 47.1% were in children 
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under fi ve. Variations in hospitalization rates for PD in 
the public sector (SUS) by year of diagnosis were small, 
except in children under one and 1 to 4, with possibly 
a general downward tendency (Table 1).
The highest hospitalization rates were seen in infants 
(Figure 1). The most common clinical syndrome was 
pneumonia (64.8% of all hospitalizations for PD) 
(Figure 2). S. pneumoniae as the cause of diseases 
(ICD-10, B95.3), sepsis and meningitis accounted for 
13.7%, 12.3%, and 9.3% of PD hospitalizations in the 
SUS, respectively.
During the study period, there were 3,165 hospitali-
zations for pneumococcal meningitis registered in the 
SIH-SUS and 4,336 hospitalizations when estimates 
for the private sector were included. During this same 
period, 4,032 cases of pneumococcal meningitis were 
registered in the SINAN, which is 7% lower than 
that seen in the SIH-SUS including estimates for the 
private sector.
A causal pathogen was identifi ed in 41.4% of hospi-
talizations for bacterial meningitis reported in the 
SIH-SUS. Pneumococcus accounted for 31.3% of 
all cases of bacterial meningitis with an identifi ed 
pathogen, with slight variation by year of diagnosis 
and age group. Assuming the same proportion of 
pneumococcal meningitis in the hospitalizations for 
“unspecified bacterial meningitis”, Pneumococcus 
accounted for an additional 4,384 hospitalizations 
due to bacterial meningitis, totalizing 7,549 hospital 
admissions for pneumococcal meningitis in the SUS.
The annual estimated hospitalization rates for PD 
by clinical syndrome and age group was based on 
SIH-SUS data and included estimates of hospitali-
zation in the private sector for all clinical syndromes 
and estimates of additional pneumococcal meningitis 
cases reported under “unspecifi ed bacterial meningitis” 
(Table 2). This approach led to a more signifi cant 
increase in hospitalization rates among children under 
one, but the general trend was unchanged.
There were 4,204 hospitalizations for pneumococcal 
sepsis in the public sector and other 1,555 were esti-
mated for the private sector, totaling 5,759 hospital 
admissions over the three-year study period.
Pneumococcus accounted for 2.6% of overall sepsis 
hospitalizations in the SIH-SUS. A causal pathogen was 
identifi ed in most sepsis cases reported in the SIH-SUS. 
“Unspecifi ed sepsis” accounted for only 6.6% of all 
hospitalizations for sepsis. The proportion of cases in 
which the etiologic agent was not identifi ed increased 
by age group, reaching 17.1% in adults aged 60 to 69 
years. The rate of Pneumococcus among all causes 
of sepsis varied according to age, and was higher in 
children aged 1 to 4 (5.2%). Ta
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There were 22,161 hospitalizations due to pneumo-
coccal pneumonia reported in the SIH-SUS. There 
were estimated an additional 7,587 hospitalizations 
when the private sector was included, totalizing 29,748 
hospitalizations.
Pneumococcus was identifi ed as the causal pathogen 
in 1% of overall hospitalizations for pneumonia 
(2,254,815) in the SIH/SUS, accounting for 1.4% of 
pneumonia hospitalizations among children under 
one and 0.7% among adolescents and adults aged 15 
to 69 years.
There were 4,687 hospital admissions due to “S. pneu-
moniae as the cause of diseases” in the SUS from 2004 
to 2006 in all age groups. An additional 1,734 hospital 
admissions were estimated in the private sector, tota-
lizing 6,421 hospitalizations.
Figure 1. Annual hospitalization rates and in-hospital case-fatality rates for pneumococcal disease in the Brazilian National 
Health System, by age group and year of diagnosis. Brazil, 2004–2006.
Source: The Brazilian National Health System Hospital Database (SIH-SUS)
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Figure 2. Distribution of hospitalizations for pneumococcal disease in the public sector, by clinical syndromes and age groups. 
Brazil, 2004–2006.
Source: The Brazilian National Health System Hospital Database (SIH-SUS)
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During the three-year period studied, 2,746 hospi-
talizations for PD in the SIH-SUS resulted in death: 
1,674 from sepsis, 672 from pneumonia, 377 from 
meningitis and 26 due to “S. pneumonia as the cause 
of diseases” (Table 3). The highest CFRs were seen 
for pneumococcal sepsis (39.8%), followed by 
pneumococcal meningitis (11.9%), pneumococcal 
pneumonia (3.0%) and “S. pneumonia as the cause of 
diseases” (2.1%) and in the older age groups (Figure 
1). Pneumococcal CFRs did not change signifi cantly 
by year of diagnosis (Table 3).
During the same period, 1,276 deaths caused by pneu-
mococcal meningitis were reported in the SINAN, 
resulting in an overall case-fatality rate of 31.7% in all 
age groups (Table 3).
DISCUSSION
The annual hospitalization rates by age in Brazil are 
similar to those reported in other studies in developed 
countries before the implementation of pneumococcal 
immunization program for children. PD age distribution 
has a “U”-shape curve with the highest rates seen in 
children under two and in those aged 60 and more.11,15,20 
The burden of PD is considerable with a large annual 
number of hospital admissions.
Comparisons of national IPD hospitalization rates are 
diffi cult since studies used different case defi nitions 
(main diagnosis or all diagnosis), hospital admission 
databases (administrative or specifi c) and rate calcula-
tion methods. However, three comparable studies found 
similar average national annual PD hospitalization rates 
in the US, England and Wales and Singapore before 
the implementation of immunization programs.14,15,22,24
Regional studies or those including only specific 
health services also call for careful comparisons. 
A study in the metropolitan area of Santiago, Chile 
based on confi rmed cases found lower average IPD 
annual hospitalization rates in children under 14, but 
PD surveillance in Chilean health care centers found 
higher rates than in our study.1,12
Comparisons for specific clinical conditions can 
help identify population and health care differences 
not evident with all-inclusive PD data. The annual 
hospitalization rates for pneumococcal meningitis in 
children and hospital CFR rates in the present study are 
considerably higher than those reported in the US and 
Spain.6,25 Antibiotic use is high in Brazil, even before 
hospital care, preventing laboratory confi rmation.23,27 
This justifi es the inclusion of the proportion of pneu-
mococcal meningitis among bacterial meningitis cases 
with unidentifi ed pathogen. We estimated two CFRs for 
pneumococcal meningitis, one based on hospital data 
(SIH-SUS), which was higher than that in developed Ta
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countries, and the other one based on mandatory 
notifi cation data (SINAN), which was even higher 
especially in infants and children under fi ve. SINAN 
data includes confi rmed cases with positive laboratory 
data, and possibly more serious cases, cases treated in 
tertiary care hospitals with higher co-morbidities rates, 
and deaths in the emergency department, not included 
in hospitalization data.
Comparisons of national annual pneumonia hospi-
talization rates are complex due to different clinical 
diagnostic practices and medical nomenclatures and 
require careful analysis. However, methods have been 
proposed to improve time series comparisons from 
both a scientifi c and a health technology assessment 
perspective.9,17 Grijalva’s study in the US found a 
higher national annual pneumococcal pneumonia 
hospitalization rates among adults (18 years and more) 
than observed in this study, even when correction to 
include private sector was considered.9 Differences 
in the access to secondary care in hospital settings, in 
care practices, health information systems, and true 
variations in population PD incidence and lethality rates 
may account for the differences in hospitalization rates 
between the two countries.
Our study has some limitations. The validity of 
administrative databases depends on data quality of 
SIH and SINAN databases.13 Our search for ICD-10 
codes in the main diagnosis at discharge may have 
underestimated PD hospitalization rates as PD may 
be listed as a secondary diagnosis or even not listed 
at all. Errors and inconsistencies in diagnostic codes 
may occur. Non-confi rmation of Pneumococcus as 
the etiological agent is also a limitation. PD rates may 
have been affected by different clinical and laboratory 
practices, such as the frequency of collecting clinical 
specimens for culture in suspected cases, antibiotic use 
and culture techniques, which may vary among diffe-
rent health facilities and Brazilian regions. Information 
on specifi c pneumococcal serotypes causing disease is 
not available in the SIH and SINAN databases.
Since information on hospitalization rates in the private 
sector is not available, we used data from a national 
household survey to estimate them in private care 
settings. This approach may have overestimated PD 
rates since PD is more frequent among poor popula-
tions who are predominantly SUS users. The propor-
tion of hospitalizations for acute serious infectious 
diseases is probably higher in the SUS. Nevertheless, 
meningitis is a notifi able disease in Brazil and we 
were able to use SINAN database to check our esti-
mates, assuming that bacterial meningitis cases always 
require hospitalization. There was a small difference 
between the estimates based on SIH-SUS data inclu-
ding hospitalizations in the private sector (4,336) and 
confi rmed cases registered in the SINAN database Ta
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(4,032). Underreporting in the SINAN is concerning. 
There were differences in both databases in the number 
of cases registered according to age with more cases 
reported in the SIH-SUS than SINAN for some age 
groups, particularly children (data not shown). In 
studies conducted in other countries, the proportion of 
underreported meningitis cases varied by etiological 
agent, and was lower for meningococcus and higher 
for other bacteria, including Pneumococcus and virus.10
Both invasive and non-invasive diseases may be regis-
tered under the pneumococcal pneumonia code. The 
diagnosis at discharge of pneumococcal pneumonia 
probably accounts for identifi ed cases of S. pneumo-
niae. The low proportion of pneumococcal pneumonia 
in all hospitalizations for pneumonia in the SUS 
(1.0% for all ages; 1.4% among infants) corroborates 
this hypothesis. In a prospective study conducted in 
Salvador, northeastern Brazil, Pneumococcus was 
identifi ed in 1.8% of blood cultures from children 
hospitalized for pneumonia.16
PD hospitalization rates are probably underestimated. 
Less severe syndromes (pneumonia and other diseases), 
for which blood cultures are less frequently taken, are 
probably underdiagnosed in routine care and underre-
presented in this study. On the other hand, more serious 
cases with death but not hospitalized were not included 
either. Despite these limitations, this study provides 
valid nationwide estimates of PD hospitalization rates.
Mild IPD, particularly pneumonia and bacteremia 
without focus may be treated at outpatient settings. 
These cases were not included in the present study. 
Non-invasive PD rates, although more frequent, are 
much more diffi cult to be estimated. The etiological 
agent is not identified in the majority of cases of 
pneumonia and otitis media. The Brazilian National 
Outpatient Database does not include diagnoses and 
standardized diagnostic data for outpatient consulta-
tions and notifi cation systems should be developed for 
these cases to be included in the estimates.
Surveillance of IPD may be improved by integrating 
information from different sources and increasing its 
sensitivity and specifi city, as seen in other countries.7 
The SIH-SUS database has a nationwide coverage, easy 
access and a great volume of data, thus it is a potential 
source to complement information from laboratory-
based and sentinel surveillance, especially in the less 
developed areas with weak surveillance systems.2
PD is a major public health problem in Brazil. This 
study points out that the use of hospitalization annual 
rates should be an important part of a PD surveillance 
that can monitor the implementation and impact of PD 
vaccination program.
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